Scientists discover why Ozempic and Wegovy weight loss eventually plateaus Date: May 25, 2026 Source: NIH/Office of the Director Summary: New NIH research reveals that semaglutide sparks different responses inside appetite-controlling brain cells, offering fresh insight into why GLP-1 weight-loss drugs dont work the same for everyone
Standardized study designs, consistent reporting methods, and better control of lifestyle and dietary variables are crucial to deepen our understanding of these interactions
By increasing serotonin availability in synaptic spaces, it: Improves mood and reduces symptoms of depression Reduces anxiety and associated physical symptoms Helps regulate sleep and appetite in patients with mood disorders Escitalopram is taken orally once daily and is metabolised primarily in the liver by cytochrome P450 enzymes (mainly CYP2C19, with minor contributions from CYP3A4 and CYP2D6)
Six subjects started to regain weight after stopping semaglutide, but after 2 years their weight was still lower than at baseline
These signs can include the drug changing color
The move marks a more aggressive approach for Novo under Chief Executive Mike Doustdar
